Finland's pharma industry has great expectations for Fimea's new role

Starting its work as of the beginning of November, the Finnish Medicines Agency Fimea plays an important role for the entire health care sector. Besides the pharmaceutical regulation tasks, Fimea is also responsible for new R&D functions which are the object of many expectations, says the country's pharmaceutical trade body, the PIF.

The new R&D functions with which the Fimea charged will expand the agency's operations from mere medicines regulation work towards pharmacotherapy development and promotion of pharmacovigilance and safety of medication. In practice, this means that Fimea must increasingly integrate its pharmaceutical competence into the health care service system. The PIF expects that the Fimea to promote this objective actively and in concrete terms.

The PIF says it has great expectations of Fimea's new responsibility to compare the health benefits obtained from new medicines in patient use with the respective costs incurred by society. This is an important task for the rapid introduction of new medicines that are beneficial for the patients and the health care system.

Calls for active engagement in dialog